Assay News and Research

RSS

NIH awards DiscoveryBioMed a Phase 2 SBIR grant for research on hypertension and cystic fibrosis

DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a $750,000 Small Business Innovations Research (SBIR) Phase 2 grant by the National Institutes of Health (NIH) to continue the research into the discovery and development of small molecules to alleviate multiple chronic human diseases including cystic fibrosis (CF), hypertension and chronic kidney diseases with hypertension.

28 Sep 2009

Quintiles opens an expanded regional facility

To enhance service offerings throughout Europe, Quintiles Transnational Corp. today announced the opening of an expanded regional facility near Edinburgh, Scotland. The purpose-built facility consolidates three buildings into a single state-of-the-art complex.

28 Sep 2009

Amorfix Life Sciences to present Amorfix's EP-vCJD blood screening test for vCJD at WFH Global Forum

Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases, announced today that its Chief Executive Officer, Dr. George Adams, will present Amorfix's EP-vCJD(TM) blood screening test for variant Creutzfeldt-Jakob Disease ("vCJD") at the Sixth World Federation of Hemophilia ("WFH") Global Forum on the Safety and Supply of Treatment Products for Bleeding Disorders in Montreal, Quebec at 11:00 am ET on Friday, September 25, 2009.

24 Sep 2009

StemCells pushing forward its SC Proven cell culture product business

StemCells, Inc. (NASDAQ:STEM) today announced organizational initiatives focused on growing its specialty SC Proven® cell culture product business and advancing the development and commercialization of its central nervous system (CNS) cell-based assay platforms for use in drug screening and drug development. These initiatives reflect the Company’s ongoing integration of the operations acquired from Stem Cell Sciences (SCS) Plc in April, and include new personnel appointments and a realignment of activities within the Company’s Cambridge, UK and Palo Alto, California locations.

23 Sep 2009

New method to identify active tuberculosis in patients

Active tuberculosis can be rapidly identified in patients with negative sputum tests by a new method, according to European researchers. Active tuberculosis (TB) is the seventh-leading cause of death worldwide, and while the diagnosis of active TB can be rapidly established when the bacteria can be identified on sputum microscopy, in about half of all cases, the TB bacterium cannot be detected, making another diagnostic option critical in efforts to control the spread of TB.

23 Sep 2009

New method to diagnose active tuberculosis

23 Sep 2009

AMRI's new research & development facility dedicated by Governor Christine Gregoire

AMRI (NASDAQ:AMRI) executives were joined by Governor Christine Gregoire in dedicating the company’s new research & development facility located in Bothell, WA. The company leased 44,000 square feet at 22215 26th Avenue SE with an option on an additional 40,000 square feet through Arden Realty, Inc. and invested approximately $8 million in fit-out costs and equipment.

23 Sep 2009

Biomagnetics, Bright Dairy enter into distribution agreement for China

Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, and malaria detection, today announced it has entered into an agreement with Bright Dairy, which is the third largest dairy products producer and marketer in China.

23 Sep 2009

Amorfix announces 100% specificity upon testing 10,000 blood donations for vCJD

Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases, today announced it has achieved 100% specificity (no reproducible false positive results) upon testing 10,000 blood donations for variant Creutzfeldt-Jakob Disease ("vCJD"). with the EP-vCJD(TM) Blood Screening Assay at l'Etablissement Français du Sang de Pyrénées Méditerrannée ("EFS-PM") in Montpellier, France.

22 Sep 2009

StemCells to take part in international networking event

StemCells, Inc. (NASDAQ:STEM) announced today its participation in the 2009 World Stem Cell Summit to be held September 21 – 23 in Baltimore, Maryland.

22 Sep 2009

Wave Direct IF system launched by Celerus Diagnostics

Based on a strategy to deliver a broad range of assays for use on the Celerus Wave® System, Jason Lusk, Vice President of Sales and Marketing, today announced the availability of Wave Direct Immunofluorescence (IF).

22 Sep 2009

Primeradx raises funds for commercialization of their technology

PrimeraDx, Inc., a privately held molecular diagnostics company, announced today that it has closed on its $20 million Series C financing. The financing was led by CHL Medical Partners and also included significant participation by many of the Company’s existing investors; Abingworth, InterWest Partners, Malaysian Technology Development Corporation, MPM Capital, Burrill & Company and the Invus Group.

21 Sep 2009

Abbott Prism HIV O Plus assay approved by FDA

The U. S. Food and Drug Administration today announced approval of the Abbott Prism HIV O Plus assay, as a screening tool designed to detect the presence of certain antibodies to HIV. The assay is one of five assays that run on the fully automated Abbott Prism System.

21 Sep 2009

Universal Detection Technology to showcase its TS-10-5-agent biodetection kit

Universal Detection Technology, a developer of early-warning monitoring technologies and counter-terrorism training programs to protect people from bioterrorism and other infectious health threats, announced today that it will be showcasing its TS-10-5-agent biodetection kit at ASIS International 2009 in Anaheim, California.

18 Sep 2009

New tool developed to provide precise and cost-effective data collection for drug discovery efforts

Cancer and cell biology experts at the University of Cincinnati (UC) have developed a new mass spectrometry-based tool they say provides more precise, cost-effective data collection for drug discovery efforts.

18 Sep 2009

Enzo expands its capability to perform simultaneous live-cell imaging of nuclear components

Enzo Life Sciences, a division of Enzo Biochem, Inc. (NYSE:ENZ), has added a novel new system to its CELLestial™ line of live cell analysis products, providing expanded capability to simultaneously image both the nucleus and the nucleolus in living cells, the Company announced today. Called the Total Nuclear-ID™ Green/Red Nucleolar/Nuclear Detection Kit, the new addition has been specifically optimized for demanding live cell microscopy applications.

17 Sep 2009

ColoMarker assay achieves 100 percent detection rate for colon cancers

Marking a major milestone in the early detection and management of colon cancer, EDP Biotech Corporation (EDP), a developer of immunodiagnostic tests for humans and animals, announced today that its ColoMarker assay achieved 100 percent detection rate for colon cancers presented at stages I through III in pre-clinical trials.

17 Sep 2009

Diagnocure reports third-quarter fiscal 2009 results

DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced revenue of $396,468 and a net loss of $4,034,364 or $0.09 per share for the third quarter ending July 31, 2009.

17 Sep 2009

Medivir presented preclinical data from its cathepsin K inhibitor program at the ASBMR meeting

Medivir (STO:MVIRB) presented preclinical data on two candidate drugs (MIV-710, MIV-711) from its cathepsin K inhibitor program in a poster session during the ASBMR (American Society for Bone and Mineral Research) meeting.

16 Sep 2009

HemoRANK-TKI in vitro assay service package from ReachBio

ReachBio LLC announced today the launch of HemoRANK(TM)-TKI, an in vitro assay service package that helps predict the potential of novel therapeutic tyrosine kinase inhibitors (TKIs) to cause clinical hematotoxicity (myelotoxicity or neutropenia).

16 Sep 2009